Maxim Group set a $6.00 target price on Vistagen Therapeutics (NASDAQ:VTGN) in a report issued on Thursday. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Oppenheimer started coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set a buy rating and a $6.00 price target for the company. Zacks Investment Research raised shares of Vistagen Therapeutics from a hold rating to a buy rating and set a $1.50 price target for the company in a research report on Thursday, August 30th. Chardan Capital reaffirmed a buy rating and set a $22.00 price target on shares of Vistagen Therapeutics in a research report on Friday, June 29th. Finally, UBS Group started coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set an outperform rating and a $6.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $8.30.

Shares of VTGN stock opened at $1.36 on Thursday. Vistagen Therapeutics has a one year low of $0.69 and a one year high of $2.65.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). sell-side analysts expect that Vistagen Therapeutics will post -0.75 earnings per share for the current fiscal year.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Further Reading: What is intrinsic value?

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.